In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas

被引:88
作者
Waites, KB
Crabb, DM
Bing, X
Duff, LB
机构
[1] Univ Alabama, Dept Pathol, Birmingham, AL 35249 USA
[2] Univ Alabama, Dept Microbiol, Birmingham, AL 35249 USA
关键词
D O I
10.1128/AAC.47.1.161-165.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 Mycoplasma pneumoniae, 45 Mycoplasma hominis, 15 Mycoplasma fermentans, and 68 Ureaplasma sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at :51 mug/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC(90)s; less than or equal to50.008 mug/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae. For M. hominis, the garenoxacin MIC90 (less than or equal to0.008 mug/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15 M. fermentans isolates were inhibited by garenoxacin at concentrations less than or equal to0.008 mug/ml, making it the most active drug tested against this organism. For Ureaplasma spp., the garenoxacin MIC90 (0.25 mug/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against M. pneumoniae and M. hominis by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 27 条
[1]   In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized [J].
Bebear, CM ;
Renaudin, H ;
Charron, A ;
Gruson, D ;
Lefrancois, M ;
Bebear, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2557-2560
[2]   In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas [J].
Bébéar, CM ;
Renaudin, H ;
Schaeverbeke, T ;
Leblanc, F ;
Bébéar, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) :711-714
[3]   Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas [J].
Bebear, CM ;
Renaudin, H ;
Bryskier, A ;
Bebear, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1980-1982
[4]   In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas [J].
Bébéar, CM ;
Renaudin, H ;
Boudjadja, A ;
Bébéar, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :703-704
[6]   In vitro susceptibility study of BMS-284756 against Legionella species [J].
Dubois, J ;
St-Pierre, C .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 41 (1-2) :79-82
[7]   Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. [J].
Duffy, LB ;
Crabb, D ;
Searcey, K ;
Kempf, MC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 :29-33
[8]   Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 [J].
Fung-Tomc, JC ;
Minassian, B ;
Kolek, B ;
Huczko, E ;
Aleksunes, L ;
Stickle, T ;
Washo, T ;
Gradelski, E ;
Valera, L ;
Bonner, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3351-3356
[9]   In vitro activities of moxifloxacin and ether fluoroquinolones against Mycoplasma pneumoniae [J].
Hamamoto, K ;
Shimizu, T ;
Fujimoto, N ;
Zhang, Y ;
Arai, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1908-1910
[10]   In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas [J].
Hannan, PCT ;
Woodnutt, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) :367-369